DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20202662

Clinico-epidemiological study of melasma in tertiary care centre

Nishtha H. Patel, Narendra Gangaiah, Veena Thimappa, Pavithra Gundappa

Abstract


Background: Melasma is common pigmentary disorder and affect patient quality of life due to its presentation over the face. It mostly affects sun exposed area and present as grey-brown pigmentation over the face.

Methods: In this observational or descriptive study, total 110 patients were enrolled which was carried out in the Department of Dermatology from February 2019 to January 2020 at Sri Siddhartha Medical College and Sciences, Tumkur, Karnataka.

Results: Mean age group affected was 31-40 years of age (41.8%). Out of 110 patients 18 patients were male and 92 patients were females. Total 15 patients had positive family history (13.6%). 30 patients had history of taking oral contraceptive pills (27.3%). 22 patients had sun exposure history (20%). 59 patients had epidermal pigmentation (53.6%) and 62 patients had malar region distribution (56.4%).

Conclusions: During third decade of life, females were more commonly affected. Pathogenesis of melasma is multifactorial. In our study, we found that oral contraceptive pills and sun exposure may predispose or trigger the melasma. Most common area affected was malar. Epidermal pigmentation was more common.


Keywords


Melasma, Clinical patterns, Oral contraceptives

Full Text:

PDF

References


Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5(4):426-35.

Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019;12(1):63-7.

Sarkar R. Melasma and quality of life: melasma a monograph 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2015: 74.

Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, Villemur JA, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab. 1985;61(1):28-31.

Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131(12):1453-7.

Nicolaidou E, Antoniou C, Katsambas AD. Origin, clinical presentation, and diagnosis of facial hypermelanoses. Dermatol Clin. 2007;25:321‑6.

Tamler C, Fonseca RM, Pereira FB, Barcaui CB. Classification of melasma by dermoscopy: Comparative study with wood’s lamp. Surg Cosmet Dermatol. 2009;1:115‑9.

Goh CL, Dlova CN. A retrospective Study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455-8.

Katsambas AD, Stratigos AJ, Lotti TM. Melasma. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Springer, Berlin; 2003: 336-341.

Resnik S. Melasma induced by oral contraceptive drug. JAMA. 1967;199:601-5.

Vazquez M, Maldonado H, Benmaman C. Melasma in men, a clinical and histological study. Int J Dermatol. 1988;27:25-7.

Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC, et al. A clinical, light microscopic, ultrastructural and immunoflorescence study. J Am Acad Dermatol. 1981;4:698-710.

Katasambas A, Antoniou C. Melasma: Classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217-23.

Thappa DM. Melasma (chloasma): A review with current treatment options. Indian J Dermatol. 2004;49:165-76.